The dual settlements represent the Department of Justice’s continued crackdown on possible False Claims Act violations.
Novartis Pharmaceuticals Corporation reached an over $642 million-dollar agreement to resolve claims of violating the False Claims Act (FCA). The company based out of East Hanover, New Jersey was involved in two settlements. The first settlement resolves allegations that the company illegally used three foundations as channels to pay the copayments of Medicare patients who were prescribed two of their drugs, Gilenya and Afinitor. The second brings resolution to an alleged payment kickback scheme to doctors.
“Through this settlement and others, the government has demonstrated its commitment to ensuring that drug companies do not use kickbacks to influence the drugs prescribed by doctors or purchased by patients,” said Assistant Attorney General Jody Hunt of the Department of Justice’s Civil Division in a Department of Justice (DOJ) press release. “We will continue to safeguard the Medicare program from kickbacks and their pernicious effects, including the undermining of important cost-control mechanisms instituted by Congress.”
With the first settlement, the company agreed to pay $51.25 million for resolution regarding the illegal payments of copay obligations for patients taking their prescriptions. Under Medicare beneficiary policy, when using a covered prescription drug, the beneficiary could be required to make a partial payment in the form of a copayment, coinsurance, or a deductible. These requirements were established as part of a strategy to provide a check on healthcare expenditures. This includes the prices that pharmaceutical manufacturers require for their drugs.
The drug Gilenya was approved for the treatment of relapsing forms of multiple sclerosis (MS) while Afinitor is used as a second-line treatment for advanced renal cell carcinoma (RCC) and also as a treatment for progressive neuroendocrine tumors of pancreatic origin (PNET).
In the case of Gilenya, Novartis apparently was informed in 2012 by the contractor managing the free drug program for Gilenya that over 300 patients receiving free prescriptions at the time would have Medicare eligibility in 2013. According to the allegations, Novartis and the contractor schemed to transition those patients to Medicare Part D, allowing Novartis to be reimbursed through Medicare when those patients filled their Gilenya prescriptions in the future. With full knowledge that patients would be unable to afford the copay for the drug, the company created a plan with a foundation that enabled Novartis to cover patient copays.
Furthermore, the company allegedly laid specific plans for payments to be made to the foundation. The actions were coordinated with the opening of the foundation’s MS fund at 6:00 PM on a Friday, with contractor personnel working overtime allowing them to submit applications for those patients prescribed free Gilenya. This resulted in a disproportionate share of the funding being directed to Gilenya patients during 2013.
With the second settlement, the pharmaceutical company is expected to pay $591,442,008 for resolution regarding a scheme of kickback payments to doctors. The company allegedly encouraged them to prescribe the Novartis drugs Lotrel, Valturna, Starlix, Tekturna, Tekturna HCT, Tekamlo, Diovan, Diovan HCT, Exforge, and Exforge HCT. Novartis will also relinquish $38.4 million under the Civil Asset Forfeiture Statute.
Along with the payments, Novartis also provided comprehensive factual admissions in the settlement while agreeing to severe limitations on future speaker programs, such as drastic reductions to the budget spent toward these programs.
“For more than a decade, Novartis spent hundreds of millions of dollars on so-called speaker programs, including speaking fees, exorbitant meals, and top-shelf alcohol that were nothing more than bribes to get doctors across the country to prescribe Novartis’s drugs,” said Acting U.S. Attorney Audrey Strauss for the Southern District of New York in the press release. “Giving these cash payments and other lavish goodies interferes with the duty of doctors to choose the best treatment for their patients and increase drug costs for everyone. This office will continue to be vigilant in cracking down on kickbacks, however, they may be dressed up, throughout the pharmaceutical industry.”
The settlement also resolves a lawsuit entitled United States ex rel. Bilotta v. Novartis Pharmaceuticals Corp., No. 11-Civ.-0071-PGG (S.D.N.Y.). The lawsuit was first filed under the whistleblower provision of the FCA. For part of this settlement, Novartis reached an agreement to pay an additional $48,151,273 for the resolution of state Medicaid claims.
Simultaneously with the FCA settlements, Novartis agreed to enter into a corporate integrity agreement (CIA) with the Department of Health and Human Services Office of Inspector General (HHS-OIG). The CIA intends to deal with the actions in both settlements. The agreement mandates the reduction of the number of paid speaker programs and the budget of the programs while limiting the circumstances under which they may occur, including restrictions to a virtual format. Additionally, measures must be in place that show and promote independence from any patient assistance programs that Novartis contributes to. Overarching multi-faceted monitoring of the company’s operations will also occur.
As often is the case in these scenarios, the claims listed and resolved through legal settlements remain allegations only with no true determination of liability.
To read the DOJ press release in its entirety, which includes further details on each of the settlements go online to https://www.justice.gov/opa/pr/novartis-pays-over-642-million-settle-allegations-improper-payments-patients-and-physicians
Programming Note: Listen to whistleblower attorney Mary Inman report this story live during Monitor Monday, July 13, 10-10:30 a.m. EST.
The 60-day Refund Rule, created by the 2010 Patient Protection and Affordable Care Act (PPACA), requires providers to report and return Medicare and Medicaid overpayments
A recent federal court decision coming out of New Jersey demonstrates the viability of an unusual kind of whistleblower: a privately defrauded party. The most
Please log in to your account to comment on this article.
ICD10monitor has teamed up with renowned CDI expert Dr. Erica Remer to bring you an exclusive webcast on how to recognize sepsis, how to get providers to give documentation that will support sepsis, and how to educate to avert sepsis denials. Register now and become a crucial piece of the solution to standardizing sepsis clinical practice, documentation, and coding at your facility.
Optimize your inpatient clinical documentation and gain comprehensive knowledge from foundational practices to advanced technologies, ensuring improved patient care and organizational and financial success. This webcast bundle provides a holistic approach to CDI, empowering you to implement best practices from the ground up and leverage advanced strategies for superior results. Participants will gain actionable insights to improve documentation quality, patient care, compliance, and financial outcomes.
Join expert Angela Comfort, MBA, RHIA, CDIP, CCS, CCS-P., as she helps you navigate advanced inpatient CDI technologies, regulatory changes, and system interoperability. Angela will provide actionable strategies for integrating AI and predictive analytics into CDI practices, ensuring seamless system interoperability, and maintaining compliance with evolving regulations. Attendees will learn to select and implement advanced EHR systems and CDI software, leverage data analytics to enhance documentation accuracy, and stay audit-ready with the latest compliance updates. Real-world case studies and practical tools will empower you to drive continuous improvement in CDI, improve patient outcomes, and enhance organizational efficiency. Don’t miss this opportunity to advance your CDI practices and stay ahead in this dynamic field.
Join expert Angela Comfort, MBA, RHIA, CDIP, CCS, CCS-P, for an insightful webcast on improving inpatient clinical documentation integrity (CDI). Inaccurate documentation can lead to misdiagnosis, improper treatment, and compromised patient safety. High workloads, lack of standardized practices, and outdated EHR systems contribute to these issues, affecting care quality and financial outcomes. Angela will offer practical strategies and tools to enhance accuracy, consistency, and timeliness in documentation. Attendees will learn to use standardized templates, checklists, and advanced EHR systems, while staying compliant with regulations. Improve patient care, ensure accurate billing, and reduce audit risks with actionable insights from this essential webcast.
This webcast, presented by Tiffany Ferguson, LMSW, CMAC, ACM, addresses the critical gap in Social Determinants of Health (SDoH) reporting for pediatric populations. While SDoH efforts often focus on adults, this session emphasizes the unique needs of children. Attendees will gain insights into the current state of SDoH, new pediatric Z-codes, and the importance of interdisciplinary collaboration. By understanding and applying pediatric-specific SDoH factors, healthcare professionals can improve data capture, compliance, and care outcomes. This webcast is essential for those looking to enhance their approach to pediatric SDoH reporting and coding.
Join Becky Jacobsen, BSN, RN, MBS, CCS-P, CPC, CPEDC, CBCS, CEMC, VP of CDM, for a webcast addressing oncology service coding challenges. Learn to navigate coding for infusions and injections alongside Evaluation and Management (E/M) services, ensuring compliance and accurate reimbursement. Gain insights into documenting E/M services for oncology patients and determining medical necessity. This webcast is essential to optimize coding practices, maintain compliance, and maximize revenue in oncology care.
During this webcast Dr. Ronald Hirsch delves into the inpatient admission order process including when to get it, when it becomes effective, its impact on billing and payment, who can write it, how to cancel it, the effects on the beneficiary, and more. You’ll leave with a clear understanding of inpatient orders and guidelines for handling improper orders that you can implement immediately.
Michelle Wieczorek explores challenges, strategies, and best practices to AI implementation and ongoing monitoring in the middle revenue cycle through real-world use cases. She addresses critical issues such as the validation of AI algorithms, the importance of human validation in machine learning, and the delineation of responsibilities between buyers and vendors.
Copyright © 2024 RACmonitor. Powered by MedLearn Media.
Happy National Doctor’s Day! Learn how to get a complimentary webcast on ‘Decoding Social Admissions’ as a token of our heartfelt appreciation! Click here to learn more →
